Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre

Surgery

Volumn 141, Issue 1, 2007, Pages 90-95

  Bugalho, Maria João ^a,b   Domingues, Rita ^b   Santos, Jorge Rosa ^a   Catarino, Ana Luísa ^a   Sobrinho, Luís ^a  

^a Portuguese Cancer Center   (Portugal)

^b INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; DNA; PENTAGASTRIN;

ADOLESCENT; ADULT; ARTICLE; CANCER CENTER; CHILD; CLINICAL FEATURE; CODON; DNA SEQUENCE; FEMALE; GENE MUTATION; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE ENDOCRINE NEOPLASIA; ONCOGENE RET; PHEOCHROMOCYTOMA; POLYMERASE CHAIN REACTION; PORTUGAL; PRIORITY JOURNAL; PROTO ONCOGENE; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; BASE SEQUENCE; CANCER CARE FACILITIES; CARCINOMA, MEDULLARY; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GERM-LINE MUTATION; HETEROZYGOTE DETECTION; HUMANS; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; PHEOCHROMOCYTOMA; PORTUGAL; PROTO-ONCOGENE PROTEINS C-RET; PROTO-ONCOGENES; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 33845507104     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2006.03.025     Document Type: Article

References (41)

1. Saad M.F., Ordonez N.G., Rashid R.K., et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine 63 (1984) 319-342
2. Raue F. German medullary thyroid carcinoma/multiple endocrine neoplasia registry. German MTC/MEN Study Group. Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia Type 2. Langenbecks Arch Surg 383 (1998) 334-336
3. Kebebew E., Ituarte P.H., Siperstein A.E., Duh Q.Y., and Clark O.H. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88 (2000) 1139-1148
4. Donis-Keller H., Dou S., Chi D., et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2 (1993) 851-856
5. Mulligan L.M., Kwok J.B., Healey C.S., et al. Germline mutations of the RET protooncogene in multiple endocrine neoplasia Type 2A. Nature 363 (1993) 458-460
6. Carlson K.M., Dou S., Chi D., et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia Type 2B. Proc Natl Acad Sci USA 91 (1994) 1579-1583
7. Eng C., Smith D.P., Mulligan L.M., et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia Type 2B and related sporadic tumours. Hum Mol Genet 3 (1994) 237-241
8. Hofstra R.M., Landsvater R.M., Ceccherini I., et al. A mutation in the RET protooncogene associated with multiple endocrine neoplasia Type 2B and sporadic medullary thyroid carcinoma. Nature 367 (1994) 375-376
9. Wells Jr. S.A., Dilley W.G., Farndon J.A., Leight G.S., and Baylin S.B. Early diagnosis and treatment of medullary thyroid carcinoma. Arch Intern Med 145 (1985) 1248-1252
10. Evans D.B., Fleming J.B., Lee J.E., Cote G., and Gagel R.F. The surgical treatment of medullary thyroid carcinoma. Semin Surg Oncol 16 (1999) 50-63
11. Fleming J.B., Lee J.E., Bouvet M., et al. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 230 (1999) 697-707
12. Gimm O., Sutter T., and Dralle H. Diagnosis and therapy of sporadic and familial medullary thyroid carcinoma. J Cancer Res Clin Oncol 127 (2001) 156-165
13. Niccoli-Sire P., Murat A., Baudin E., et al. Early or prophylactic thyroidectomy in MEN 2/FMTC gene carriers: results in 71 thyroidectomized patients. The French Calcitonin Tumours Study Group (GETC). Eur J Endocrinol 141 (1999) 468-474
14. Machens A., Niccoli-Sire P., Hoegel J., et al. European Multiple Endocrine Neoplasia (EUROMEN) Study Group. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349 (2003) 1517-1525
15. Skinner M.A., Moley J.A., Dilley W.G., Owzar K., Debenedetti M.K., and Wells Jr. S.A. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 353 (2005) 1105-1113
16. Bowtell D.D. Rapid isolation of eukaryotic DNA. Anal Biochem 162 (1987) 463-465
17. Mulligan L.M., Eng C., Attie T., et al. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet 3 (1994) 2163-2167
18. Ceccherini I., Hofstra R.M., Luo Y., et al. DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene. Oncogene 9 (1994) 3025-3029
19. Pigny P., Bauters C., Wemeau J.L., et al. A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. J Clin Endocrinol Metab 84 (1999) 1700-1704
20. Eng C., Clayton D., Schuffenecker I., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276 (1996) 1575-1579
21. Komminoth P., Kunz E.K., Matias-Guiu X., Hiort O., Christiansen G., Colomer A., et al. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Cancer 76 (1995) 479-489
22. Eng C., Smith D.P., Mulligan L.M., et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10 (1995) 509-513
23. Bolino A., Schuffenecker I., Luo Y., et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10 (1995) 2415-2419
24. Hofstra R.M., Fattoruso O., Quadro L., et al. A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 82 (1997) 4176-4178
25. Berndt I., Reuter M., Saller B., et al. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83 (1998) 770-774
26. Eng C., Mulligan L.M., Smith D.P., et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol 43 (1995) 123-127 (Oxf)
27. Wohllk N., Cote G.J., Bugalho M.M., et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81 (1996) 3740-3745
28. Schuffenecker I., Ginet N., Goldgar D., et al. Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine. Am J Hum Genet 60 (1997) 233-237
29. Wiench M., Wygoda Z., Gubala E., et al. Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. J Clin Oncol 19 (2001) 1374-1380
30. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996. J Clin Oncol 14 (1996) 1730-1736
31. Sakai T., Wakizaka A., Matsuda H., Nirasawa Y., and Itoh Y. Point mutation in exon 12 of the receptor tyrosine kinase proto-oncogene RET in Ondine-Hirschsprung syndrome. Pediatrics 101 (1998) 924-926
32. Uchino S., Noguchi S., Yamashita H., et al. Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type. Jpn J Cancer Res 90 (1999) 1231-1237
33. Niccoli-Sire P., Murat A., Rohmer V., et al. Calcitonin Tumors Group (GETC). Familial medullary thyroid carcinoma with noncysteine RET mutations: phenotype-genotype relationship in a large series of patients. J Clin Endocrinol Metab 86 (2001) 3746-3753
34. Da Silva A.M., Maciel R.M., Da Silva M.R., et al. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 88 (2003) 5438-5443
35. Dvorakova S., Vaclavikova E., Duskova J., Vlcek P., Ryska A., and Bendlova B. Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg. J Endocrinol Invest 28 (2005) 905-909
36. Nunziata V., Giannattasio R., Di Giovanni G., D'Armiento M.R., and Mancini M. Hereditary localized pruritus in affected members of a kindred with multiple endocrine neoplasia Type 2A (Sipple's syndrome). Clin Endocrinol 30 (1989) 57-63
37. Gagel R.F., Levy M.L., Donovan D.T., Alford B.R., Wheeler T., and Tschen J.A. Multiple endocrine neoplasia Type 2A associated with cutaneous lichen amyloidosis. Ann Intern Med 111 (1989) 802-806
38. Bugalho M.J., Limbert E., Sobrinho L.G., et al. A kindred with multiple endocrine neoplasia Type 2A associated with pruritic skin lesions. Cancer 70 (1992) 2664-2667
39. Lips C.J., Landsvater R.M., Hoppener J.W., et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 331 (1994) 828-835
40. Brandi M.L., Gagel R.F., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 (2001) 5658-5671
41. Machens A., Ukkat J., Brauckhoff M., Gimm O., and Dralle H. Advances in the management of hereditary medullary thyroid cancer. J Intern Med 257 (2005) 50-59